source
- Moderna and Merck's mRNA cancer vaccine extends survival in phase 3 melanoma trialMerck and Moderna reported that their personalized mRNA cancer vaccine improved patient outcomes in a late-stage study. The phase 3 INTerpath-001 trial enrolled 1,137 patients who had surgery to r…
- Alumis' TYK2 inhibitor flunks mid-stage lupus trial, shares drop 55%Alumis reported that its experimental TYK2 inhibitor, envudeucitinib, failed to meet any primary or secondary endpoints in a mid-stage study of systemic lupus erythematosus. The company highlighte…